Investigator(s):
The Lundquist Institute
LOS ANGELES – (August 1, 2013) – The rise of antibiotic resistance among hospital-acquired infections is greater than the Centers for Disease Control and Prevention (CDC) found in its 2008 analysis, according to an ahead-of-print article in the journal,Antimicrobial Agents and Chemotherapy.
The article also finds that the Food and Drug Administration’s (FDA) promise to “reboot” antibiotic development rules a year ago to combat the rise in resistance has fallen short.
Investigator(s):
The Lundquist Institute
For more than 60 years, the researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have been pioneering the medical advances that are saving lives and improving the health of people in the region and around the world.
Little, if any, of this would be possible without the support of the federal government through the National Institutes of Health (NIH).
Investigator(s):
The Lundquist Institute
Hormone replacement therapy has plummeted among U.S. women since the Women’s Health Initiative cut short its Estrogen Plus Progestin Trial in 2002, when study results revealed that women who took the two-hormone therapy suffered adverse effects and higher mortality.
But the widespread rejection since of all hormone replacement therapies among menopausal women has been misguided, a team of researchers from the Yale School of Medicine in New Haven, Conn., wrote Thursday in the online edition of the American Journal of Public Health.
Read more at:
Investigator(s):
The Lundquist Institute
SAN FRANCISCO – (June 18, 2013) – Men who lose sleep during the work week may be able to lower their risk of developing Type 2 diabetes by getting more hours of sleep, according to Los Angeles Biomedical Research Institute (LA BioMed) research findings presented today at The Endocrine Society’s 95th Annual Meeting in San Francisco.
Investigator(s):
The Lundquist Institute
Dr Matthew Budoff (Los Angeles Biomedical Research Institute, CA), a longtime researcher in the use of cardiac CT, described what he believes to be the most important uses for CT today [1].
First, CT angiography is emerging as “a single tool that gives us [information about] function and anatomy,” he told the audience.
Investigator(s):
Virender Rehan, MD
Turmeric, a key ingredient in spicy curry dishes, has long been known to have medicinal values. Now new research finds a substance in turmeric, curcumin, may provide lasting protection against potentially deadly lung damage in premature infants.
Investigator(s):
The Lundquist Institute
LOS ANGELES – (May 29, 2013) – Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center(LA BioMed) has named three new members to its board of directors.
The new members are Alex Popa, a vice president at The Capital Group in Los Angeles; H. Michael Smith, the national science and technology practice leader for HKS, Inc.; and Sussan Sharifian, president of Packair Airfreight, Inc and Packair Customs Brokers, Inc.
Investigator(s):
Carol D Berkowitz, MD, Mallory Witt, MD
LOS ANGELES – (May 28, 2013) – Carol Berkowitz, MD, and Mallory D. Witt, MD, lead researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), received the Serge & Yvette Dadone Clinical Teaching Award in Honor of Saleh Salehmoghaddam, M.D., a peer-reviewed recognition of their “outstanding dedication, innovation, and sustained excellence in clinical and classroom teaching,” according to the David Geffen School of Medicine at UCLA, which presented the awards.
Investigator(s):
Yan Xiong, MD, PhD
Drs. Arnold Bayer, Yan Qiong Xiong and Soo-Jin Yang, Faculty principal investigators in LA BioMed’s Division of Infectious Diseases, have recently been awarded three extramural grants for their collaborating programs in the study of Staphylococcus aureus infections, most specifically Methicillin-resistant Staphylococcus aureus (MRSA). Dr. Bayer’s $1.8 million grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) represents continued funding for years 15-19 of this RO1-funded project, while Dr.